In addition, the melanoma was reported to weaken immunotherapy by releasing Wnt5a, which induced indoleamine 2,3-dioxygenase 1 activity in dendritic cells and reduced the efficacy of programmed cell death protein 1 (PD-1) blockade therapy (109). Here, PDCD1 is linked to melanoma.